Predictive cancer genomics - what do we need?

被引：17

作者：

Brenton, JD ^{[1
]}

Caldas, C ^{[1
]}

机构：

[1] Univ Cambridge, Dept Oncol, Canc Genom Program, Hutchison MRC Res Ctr, Cambridge CB2 2XZ, England

来源：

LANCET | 2003年 / 362卷 / 9381期

关键词：

D O I：

10.1016/S0140-6736(03)14053-6

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：340 / 341

页数：2

共 10 条

[1] A guide to microarray experiments - an open letter to the scientific journals [J].

Ball, CA ;

Sherlock, G ;

Parkinson, H ;

Rocca-Sera, P ;

Brooksbank, C ;

Causton, HC ;

Cavalieri, D ;

Gaasterland, T ;

Hingamp, P ;

Holstege, F ;

Ringwald, M ;

Spellman, P ;

Stoeckert, CJ ;

Stewart, JE ;

Taylor, R ;

Brazma, A ;

Quackenbush, J .

LANCET, 2002, 360 (9338) :1019-1019

[2] PRIMARY CHEMOTHERAPY TO AVOID MASTECTOMY IN TUMORS WITH DIAMETERS OF 3 CENTIMETERS OR MORE [J].

BONADONNA, G ;

VERONESI, U ;

BRAMBILLA, C ;

FERRARI, L ;

LUINI, A ;

GRECO, M ;

BARTOLI, C ;

DEYOLDI, GC ;

ZUCALI, R ;

RILKE, F ;

ANDREOLA, S ;

SILVESTRINI, R ;

DIFRONZO, G ;

VALAGUSSA, P .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1990, 82 (19) :1539-1545

[3] Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer [J].

Chollet, P ;

Amat, S ;

Cure, H ;

de Latour, M ;

Le Bouedec, G ;

Mouret-Reynier, MA ;

Ferriere, JP ;

Achard, JL ;

Dauplat, J ;

Penault-Llorca, F .

BRITISH JOURNAL OF CANCER, 2002, 86 (07) :1041-1046

[4] Different responses to preoperative chemotherapy for invasive lobular and invasive ductal breast carcinoma [J].

Cocquyt, VF ;

Blondeel, PN ;

Depypere, HT ;

Praet, MM ;

Schelfhout, VR ;

Silva, OE ;

Hurley, J ;

Serreyn, RF ;

Daems, KK ;

Van Belle, SJP .

EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 2003, 29 (04) :361-367

[5] Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome [J].

Faneyte, IF ;

Schrama, JG ;

Peterse, JL ;

Remijnse, PL ;

Rodenhuis, S ;

van der Vijver, MJ .

BRITISH JOURNAL OF CANCER, 2003, 88 (03) :406-412

[6] Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy [J].

Kuerer, HM ;

Newman, LA ;

Smith, TL ;

Ames, FC ;

Hunt, KK ;

Dhingra, K ;

Theriault, RL ;

Singh, G ;

Binkley, SM ;

Sneige, N ;

Buchholz, TA ;

Ross, MI ;

McNeese, MD ;

Buzdar, AU ;

Hortobagyi, GN ;

Singletary, SE .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (02) :460-469

[7]

*NAT CANC I, CACORE NCICB CANC IN

[8]

*NCBI, GEN EXP OMN

[9] Medical applications of microarray technologies: a regulatory science perspective [J].

Petricoin, EF ;

Hackett, JL ;

Lesko, LJ ;

Puri, RK ;

Gutman, SI ;

Chumakov, K ;

Woodcock, J ;

Feigal, DW ;

Zoon, KC ;

Sistare, FD .

NATURE GENETICS, 2002, 32 (Suppl 4) :474-479

[10] PRIMARY MEDICAL (NEOADJUVANT) CHEMOTHERAPY FOR OPERABLE BREAST-CANCER [J].

SMITH, IE ;

JONES, AL ;

OBRIEN, MER ;

MCKINNA, JA ;

SACKS, N ;

BAUM, M .

EUROPEAN JOURNAL OF CANCER, 1993, 29A (12) :1796-1799

← 1 →